Côd QR

BRCA2 reversion mutation confers resistance to olaparib in breast cancer

Key Clinical Message A rare missense mutation was identified as a reversion mutation using cancer genomic profiling and a suspected mechanism underlying resistance to olaparib in breast cancer. Abstract A 34‐year‐old woman with breast cancer and BRCA2: p.Gln3047Ter was treated with olaparib. After t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Shinya Yamamoto, Kei Kawashima, Yoshie Fujiwara, Shoko Adachi, Kazutaka Narui, Chiaki Hosaka, Rina Takahashi, Sho Tsuyuki, Makoto Sugimori, Miki Tanoshima, Mahato Sasamoto, Masanori Oshi, Akimitsu Yamada, Chikara Kunisaki, Itaru Endo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wiley 2023-06-01
Cyfres:Clinical Case Reports
Pynciau:
BRCA
breast neoplasms
genomics
olaparib
Mynediad Ar-lein:https://doi.org/10.1002/ccr3.7537
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg